PrepSolution

Nursing · Study journal

FNP Respiratory Practice Questions: Asthma, COPD and Pneumonia

Thirteen original FNP respiratory questions on GINA 2026 asthma rules, GOLD COPD diagnosis, ATS/IDSA outpatient pneumonia and USPSTF lung screening, each keyed to a named source.

By Elena R.Published Reviewed by PrepSolution Editorial Team11 min read
Inside this articleNursing
Section preview 01

Asthma

A 24-year-old with asthma has symptoms about twice a month and uses an albuterol inhaler only when needed. Which statement matches GINA 2026?

Read this section
On this page

Respiratory items on the FNP boards reward knowing which guideline owns the question. Asthma questions follow GINA, COPD questions follow GOLD, pneumonia follows the ATS/IDSA guideline, and screening follows USPSTF. Most wrong answers on these items come from applying an older rule, such as treating mild asthma with a rescue inhaler alone.

The 13 questions below are written for candidates using FNP-C exam prep. The NPCB blueprint weights Assess at 32% and Diagnose and Plan at 27% each, and adults make up most of the age weighting, so every item here is an adult or adolescent primary-care decision. The AANP FNP exam blueprint guide explains the full weighting.

This set is exam practice written from the guidelines, USPSTF recommendations and FDA labels listed under References. The questions are original PrepSolution items, not NPCB or ANCC exam questions. It is not clinical guidance for any patient, and it has not been reviewed by a credentialed nurse practitioner.

Asthma

Question 1: Mild asthma on albuterol alone

A 24-year-old with asthma has symptoms about twice a month and uses an albuterol inhaler only when needed. Which statement matches GINA 2026?

  • A. Albuterol alone is appropriate because symptoms are infrequent
  • B. Add a daily leukotriene receptor antagonist and keep albuterol
  • C. Asthma should not be treated with as-needed SABA alone; as-needed low-dose ICS-formoterol is the preferred reliever
  • D. Start a long-acting beta2-agonist alone for symptom control

Best answer: C. GINA recommends that asthma should not be treated solely with as-needed SABA, because SABA-only treatment is linked to more exacerbations and a higher risk of asthma death. GINA names low-dose ICS-formoterol as the preferred reliever because it lowers the risk of severe exacerbations compared with a SABA reliever.

  • A is not the best answer. Infrequent symptoms do not make SABA-only treatment safe; GINA states that people with mild symptoms can still have severe or fatal exacerbations.
  • B is not the best answer. A leukotriene receptor antagonist is not the GINA preferred reliever and the plan still leaves SABA as the only reliever.
  • D is not the best answer. LABA without an inhaled corticosteroid increases the risk of serious asthma-related events.

Question 2: Grading symptom control

Over the past 4 weeks, a 45-year-old using a SABA reliever reports daytime symptoms three times a week, waking at night with asthma once, and using the reliever four times a week. She has no activity limitation. How does GINA classify her symptom control?

  • A. Well controlled
  • B. Partly controlled
  • C. Controlled, because she has no activity limitation
  • D. Uncontrolled

Best answer: D. GINA asks four questions about the past 4 weeks: daytime symptoms more than twice a week, any night waking, SABA reliever needed more than twice a week, and any activity limitation. She answers yes to three. Three or four yes answers means uncontrolled.

  • A is not the best answer. Well controlled requires none of the four.
  • B is not the best answer. Partly controlled is one or two yes answers.
  • C is not the best answer. One negative answer does not make asthma controlled; the count of yes answers decides the level.

Question 3: A risk factor that hides behind good control

A 30-year-old reports few asthma symptoms but has filled four 200-dose albuterol canisters in the past year. How should this be interpreted under GINA?

  • A. It is a risk factor for exacerbations even when symptoms are few
  • B. It shows good control because symptoms are rare
  • C. It matters only if spirometry is abnormal
  • D. It is relevant only in children

Best answer: A. GINA lists over-use of SABA, defined as 3 or more 200-dose canisters a year, among the factors that raise the risk of exacerbations even in a person with few asthma symptoms.

  • B is not the best answer. Few symptoms do not cancel the risk; GINA lists SABA over-use as a risk factor in exactly this situation.
  • C is not the best answer. The risk factor is defined by canister use, not by spirometry.
  • D is not the best answer. The GINA risk factor list applies to adults and adolescents as well as children.

Question 4: Long-acting beta2-agonists without a steroid

Which statement about long-acting beta2-agonist (LABA) monotherapy for asthma matches the fluticasone/salmeterol (Advair Diskus) label?

  • A. LABA monotherapy is preferred for patients who dislike steroids
  • B. LABA monotherapy increases the risk of serious asthma-related events
  • C. LABA monotherapy is safe once symptoms are controlled
  • D. LABA monotherapy carries risk only in adults over 65

Best answer: B. The label states that LABA monotherapy increases the risk of serious asthma-related events, and that trial data suggest it increases the risk of asthma-related hospitalization in pediatric and adolescent patients. In fixed-dose combination with an inhaled corticosteroid, large trials did not show a significant increase in serious asthma-related events compared with ICS alone.

  • A is not the best answer. Preference does not change the risk; the label warns against LABA monotherapy.
  • C is not the best answer. Symptom control does not make LABA monotherapy safe.
  • D is not the best answer. The label describes the risk in pediatric and adolescent patients as well.

COPD

Question 5: Confirming COPD

A 66-year-old former smoker has chronic dyspnea and cough. Which finding confirms COPD under GOLD 2026?

  • A. Post-bronchodilator FEV1/FVC below 0.7 on spirometry
  • B. Hyperinflation on chest x-ray
  • C. Oxygen saturation of 91% at rest
  • D. A smoking history of more than 20 pack-years

Best answer: A. GOLD states that spirometry showing a post-bronchodilator FEV1/FVC below 0.7 is mandatory to establish the diagnosis of COPD.

  • B is not the best answer. Imaging findings do not establish the diagnosis; spirometry does.
  • C is not the best answer. A low resting saturation is not a diagnostic criterion.
  • D is not the best answer. Exposure history raises suspicion but does not confirm COPD without spirometry.

Question 6: Home oxygen in stable COPD

A 71-year-old with stable COPD has moderate oxygen desaturation with exercise but not severe resting hypoxemia. What does GOLD 2026 say about long-term oxygen therapy (LTOT)?

  • A. Prescribe LTOT for all patients who desaturate with exercise
  • B. Prescribe LTOT once FEV1 falls below 50%
  • C. LTOT should not be prescribed routinely for moderate desaturation; it may improve survival in severe resting chronic hypoxemia
  • D. LTOT is indicated whenever dyspnea limits walking

Best answer: C. GOLD says LTOT should not be prescribed routinely for stable COPD with resting or exercise-induced moderate desaturation, but that it may improve survival in patients with severe resting chronic hypoxemia.

  • A is not the best answer. Exercise desaturation alone is the situation in which GOLD says not to prescribe LTOT routinely.
  • B is not the best answer. GOLD ties the survival benefit to severe resting hypoxemia, not to an FEV1 threshold.
  • D is not the best answer. Dyspnea alone is not the GOLD indication for LTOT.

Community-acquired pneumonia

Question 7: A healthy outpatient

A 29-year-old with no comorbidities and no risk factors for resistant organisms has community-acquired pneumonia and is treated as an outpatient. Which choice matches the ATS/IDSA strong recommendation?

  • A. Levofloxacin
  • B. Amoxicillin
  • C. Amoxicillin/clavulanate plus azithromycin
  • D. Azithromycin regardless of local resistance

Best answer: B. For healthy outpatient adults without comorbidities or risk factors for resistant pathogens, ATS/IDSA recommends amoxicillin (strong recommendation), or doxycycline, or a macrolide only where pneumococcal macrolide resistance is under 25%.

  • A is not the best answer. A respiratory fluoroquinolone is a monotherapy option for outpatients with comorbidities, not the first choice for a healthy adult.
  • C is not the best answer. Combination therapy is the regimen for outpatients with comorbidities.
  • D is not the best answer. A macrolide is recommended only in areas where pneumococcal macrolide resistance is under 25%.

Question 8: An outpatient with comorbidities

A 68-year-old with diabetes and chronic heart failure has community-acquired pneumonia and is treated as an outpatient. Which approach matches ATS/IDSA?

  • A. Amoxicillin alone
  • B. Doxycycline alone
  • C. No antibiotic until a sputum culture returns
  • D. Combination therapy such as amoxicillin/clavulanate with a macrolide or doxycycline, or monotherapy with a respiratory fluoroquinolone

Best answer: D. For outpatients with comorbidities such as chronic heart, lung, liver or renal disease, diabetes, alcoholism, malignancy or asplenia, ATS/IDSA recommends combination therapy (for example amoxicillin/clavulanate with a macrolide or doxycycline) or monotherapy with a respiratory fluoroquinolone.

  • A is not the best answer. Amoxicillin alone is the healthy-adult regimen.
  • B is not the best answer. Doxycycline alone is also a healthy-adult option; with comorbidities it is used in combination.
  • C is not the best answer. ATS/IDSA recommends against routine sputum culture for outpatients, so waiting for one delays treatment.

Question 9: Sputum testing in the office

For an adult with community-acquired pneumonia managed as an outpatient, what does ATS/IDSA recommend about sputum Gram stain and culture?

  • A. Obtain them before every antibiotic start
  • B. Obtain them only if the patient is over 65
  • C. Do not obtain them routinely
  • D. Obtain them at the 5-day follow-up visit

Best answer: C. ATS/IDSA recommends not obtaining sputum Gram stain and culture routinely in adults with CAP managed in the outpatient setting. Pretreatment cultures are recommended for certain hospitalized patients.

  • A is not the best answer. Routine pretreatment testing is not recommended for outpatients.
  • B is not the best answer. Age is not the criterion in the recommendation.
  • D is not the best answer. A follow-up culture is not part of the recommendation.

Question 10: How long to treat

A 52-year-old with community-acquired pneumonia is afebrile and clinically stable on day 3 of antibiotics. What does ATS/IDSA say about the total duration?

  • A. Treat for a minimum of 5 days, even if stable before day 5
  • B. Stop on the day clinical stability is reached
  • C. Treat for 14 days for all patients
  • D. Continue until a follow-up chest x-ray is clear

Best answer: A. ATS/IDSA recommends a minimum of 5 days of antibiotics, even if the patient reaches clinical stability before day 5. Most patients reach stability within 48 to 72 hours, so 5 days is appropriate for most.

  • B is not the best answer. Stopping at stability before day 5 falls short of the minimum.
  • C is not the best answer. Fourteen days is not the standard duration in the guideline.
  • D is not the best answer. The guideline suggests not routinely obtaining follow-up imaging when symptoms resolve within 5 to 7 days.

Screening and prevention

Question 11: Lung cancer screening eligibility

Which patient meets the USPSTF criteria for annual low-dose CT lung cancer screening?

  • A. A 47-year-old who smokes with a 30 pack-year history
  • B. A 70-year-old with a 40 pack-year history who quit 18 years ago
  • C. A 58-year-old who has never smoked but has a family history of lung cancer
  • D. A 64-year-old with a 25 pack-year history who quit 6 years ago

Best answer: D. USPSTF recommends annual LDCT for adults 50 to 80 with a 20 pack-year history who currently smoke or quit within the past 15 years. The 64-year-old meets age, exposure and quit-time criteria. Grade B.

  • A is not the best answer. At 47, the patient is below the starting age of 50.
  • B is not the best answer. Screening stops once a person has not smoked for 15 years; this patient quit 18 years ago.
  • C is not the best answer. Eligibility is based on age and smoking history, not family history alone.

Question 12: Pneumococcal vaccine age

A healthy 52-year-old has never received a pneumococcal conjugate vaccine. What does current CDC guidance recommend?

  • A. Wait until age 65
  • B. Give a pneumococcal conjugate vaccine (PCV15, PCV20 or PCV21) now
  • C. Vaccinate only if a chronic lung condition is present
  • D. Give the vaccine only after a pneumonia episode

Best answer: B. CDC recommends pneumococcal vaccination for all adults 50 or older and says to give PCV15, PCV20 or PCV21 to adults 50 or older who have never received a pneumococcal conjugate vaccine or whose history is unknown.

  • A is not the best answer. The routine age is now 50, not 65.
  • C is not the best answer. Routine vaccination at 50 does not depend on a chronic condition.
  • D is not the best answer. Vaccination is preventive and is not tied to a prior infection.

Question 13: Helping an adult quit smoking

A 36-year-old, not pregnant, smokes a pack a day and wants to quit. What does USPSTF recommend?

  • A. Advise quitting and recommend e-cigarettes as the first step
  • B. Advise quitting and provide behavioral interventions and FDA-approved pharmacotherapy
  • C. Offer pharmacotherapy only after a failed attempt with counseling alone
  • D. Refer to a specialist; primary care counseling is not effective

Best answer: B. USPSTF recommends asking all adults about tobacco use, advising them to stop, and providing behavioral interventions and FDA-approved pharmacotherapy to nonpregnant adults who use tobacco. Grade A.

  • A is not the best answer. USPSTF found the evidence insufficient on e-cigarettes for cessation and directs patients to interventions with proven effectiveness and established safety.
  • C is not the best answer. The recommendation pairs behavioral support and pharmacotherapy; it does not require a failed attempt first.
  • D is not the best answer. The recommendation is addressed to clinicians in primary care.

Which source owns which question?

TopicSourceRule tested
Asthma relieverGINA 2026No SABA-only treatment; low-dose ICS-formoterol is the preferred reliever
Asthma controlGINA 2026Four questions, past 4 weeks: 0 well, 1 or 2 partly, 3 or 4 uncontrolled
COPD diagnosisGOLD 2026Post-bronchodilator FEV1/FVC below 0.7
Outpatient CAPATS/IDSA 2019Healthy: amoxicillin, doxycycline or macrolide (resistance under 25%); comorbid: combination or respiratory fluoroquinolone
CAP durationATS/IDSA 2019At least 5 days
Lung cancer screeningUSPSTF 2021 (B)Ages 50 to 80, 20 pack-years, smoking now or quit within 15 years
Pneumococcal vaccineCDC 2026All adults 50 and older
Guidelines used in this set and the rule each question turned on.

How should you use this set?

Read the stem for the details that pick the guideline row: age, comorbidities, symptom frequency, quit date. The CAP items turn on comorbidities, and the lung screening item turns on years since quitting. When you miss one, write down the threshold you used and the one the source uses. For drug-safety rules that appear across systems, the FNP pharmacology practice set covers boxed warnings and label contraindications, and the cardiovascular set covers the USPSTF prevention grades for heart disease.

For timed questions across every domain and age group on the blueprint, see FNP-C exam prep.

Elena R.

PrepSolution Content Editor, Nurse Practitioner Certification

About PrepSolution

References

  1. [1] GINA (2026). Summary Guide for Asthma Management and Prevention (2026). GINA. GINA
  2. [2] GOLD (2026). Pocket Guide to COPD Diagnosis, Management and Prevention (2026 Report). GOLD. GOLD
  3. [3] ATS/IDSA (2019). Diagnosis and Treatment of Adults with Community-acquired Pneumonia. ATS/IDSA. ATS/IDSA
  4. [4] CDC (2026). Pneumococcal Vaccine Recommendations. CDC. CDC
  5. [5] USPSTF (2021). Lung Cancer: Screening. USPSTF. USPSTF
  6. [6] USPSTF (2021). Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions. USPSTF. USPSTF
  7. [7] FDA label (2026). Advair Diskus (fluticasone propionate and salmeterol). FDA label. FDA label
  8. [8] NPCB (2026). FNP Candidate Handbook (June 2026). NPCB. NPCB

Help us improve this guide

How helpful was this article?

One tap helps us understand what’s useful.

Not helpful → Very helpful

Frequently asked questions

NPCB does not publish its item references. GINA is the most widely used international asthma strategy, and its 2026 report says asthma should not be treated with as-needed SABA alone.

Low-dose ICS-formoterol, because it reduces the risk of severe exacerbations compared with a SABA reliever.

GOLD requires a post-bronchodilator FEV1/FVC below 0.7.

ATS/IDSA strongly recommends amoxicillin. Doxycycline is a conditional alternative, and a macrolide is an option only where pneumococcal macrolide resistance is under 25%.

USPSTF recommends annual low-dose CT for adults 50 to 80 with a 20 pack-year history who smoke now or quit within the past 15 years.

No. They are original PrepSolution items written from the sources listed under References. They are not clinical guidance and have not been reviewed by a credentialed nurse practitioner.

Keep practicing for the FNP-C.

Review the study tools, access options and price, or start with free practice.

Related Articles